12:00 AM
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BAN2401: Phase II started

Eisai disclosed in its 1Q13 earnings for the period ending June 30 that it began a double-blind, placebo-controlled, U.S. and European Phase II trial to compare bi-weekly 2.5, 5 or 10 mg/kg IV BAN2401 vs. once-monthly 5 and 10...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >